Tag: Clare O’Brien
Three firms act on BioNTech’s USD950m China partner buyout
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
Japanese corporates have been actively turning to the overseas M&A market for expanding their business and enhancing capital efficiency
A-list partners share their personal rituals for sustaining performance in increasingly demanding work environments